Related Experiment Video
Updated: May 5, 2026
In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function
Published on: October 16, 2013
Interleukin 4 inhibits in vitro proliferation of leukemic and normal human B cell precursors
D Pandrau1, S Saeland, V Duvert
1Laboratory for Immunological Research, Schering-Plough, Dardilly, France.
Insights
Interleukin-4 (IL-4) inhibits the proliferation of both normal and leukemic human B cell precursors (BCP). However, IL-4 does not promote the differentiation of BCP into mature B cells.
Area of Science:
- Immunology
- Hematology
- Cell Biology
Background:
- Interleukin-4 (IL-4) is a cytokine with pleiotropic effects on immune cells.
- B cell precursors (BCP) are crucial for B cell development and are implicated in B lineage acute lymphoblastic leukemia (BCP-ALL).
Purpose of the Study:
- To investigate the impact of IL-4 on the proliferation and differentiation of human BCP.
- To determine if IL-4 influences leukemic BCP in BCP-ALL and normal BCP.
Main Methods:
- Primary human BCP (normal and leukemic) were cultured with IL-4.
- Proliferation was assessed by [3H]-thymidine incorporation.
- Cell surface antigen expression (CD20, sIgM) and cytoplasmic mu chain were analyzed by flow cytometry.
Main Results:
- IL-4 significantly inhibited spontaneous proliferation in BCP-ALL cells (8/14) and normal BCP.
- Maximum inhibition was observed at 10 U/ml IL-4, neutralized by anti-IL-4 antibody.
- IL-4 induced CD20 expression on some BCP-ALL cells but not normal BCP.
- IL-4 did not induce cytoplasmic mu chain or sIgM expression on either cell type.
Conclusions:
- IL-4 exhibits inhibitory effects on both normal and leukemic human B cell proliferation.
- IL-4 does not induce differentiation from B cell precursors to mature B cells.
- These findings highlight a potential role for IL-4 in regulating B lymphopoiesis and BCP-ALL.
Abstract:
In the present study, we have investigated the effects of IL-4 on the proliferation and differentiation of leukemic and normal human B cell precursors (BCP). We have demonstrated that IL-4 significantly inhibited spontaneous [3H]thymidine ([3H]-TdR) incorporation by leukemic blasts from some B lineage acute lymphoblastic leukemia (BCP-ALL) patients (8 of 14). Furthermore, IL-4 was found to suppress the spontaneous and factor-dependent (IL-7 and IL-3) proliferation of normal BCP (CD10+ surface [s] IgM- cells) isolated from fetal bone marrow. Maximum growth inhibition of either leukemic or normal BCP was reached at low IL-4 concentrations (10 U/ml), and the effect was specifically neutralized by anti-IL-4 antibody. IL-4 was further found to induce the expression of CD20 antigen on BCP-ALL cells from a number of the cases examined (5 of 8), but in contrast to leukemic cells, IL-4 failed to induce CD20 antigen on normal BCP. Finally, IL-4 was found to induce neither the expression of cytoplasmic mu chain, nor the appearance of sIgM+ cells in cultures of normal or leukemic BCP. Our data indicate that IL-4 has the potential to inhibit cell proliferation in leukemic and normal human B lymphopoiesis but is unable to drive the transition from BCP to mature B cells.
